Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program ... Read More
Enveda Biosciences secures $55m to advance AI-driven drug discovery
Enveda Biosciences, a leader in utilizing artificial intelligence (AI) to convert nature’s chemistry into groundbreaking medicines, has successfully raised an additional $55 million. This funding ... Read More
Oncocross and JW Pharmaceutical forge new path in AI-driven drug development
In a significant stride toward revolutionizing drug discovery and development, Seoul-based biotech firm Oncocross announced on May 22nd a renewed joint research agreement with JW ... Read More
Accenture invests in Turbine to advance AI-powered drug discovery
Accenture (NYSE: ACN) has announced a strategic investment through Accenture Ventures into Turbine, a pioneering predictive simulation company. This investment aims to enhance Turbine’s capabilities ... Read More